ANAVEX2-73 oral liquid + Placebo oral liquid
Phase 2/3Completed 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rett Syndrome
Conditions
Rett Syndrome
Trial Timeline
Jul 1, 2020 → Jun 30, 2023
NCT ID
NCT04304482About ANAVEX2-73 oral liquid + Placebo oral liquid
ANAVEX2-73 oral liquid + Placebo oral liquid is a phase 2/3 stage product being developed by Anavex Life Sciences for Rett Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04304482. Target conditions include Rett Syndrome.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04304482 | Phase 2/3 | Completed |
Competing Products
20 competing products in Rett Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Esomeprazole + Aspirin + Rofecoxib | AstraZeneca | Approved | 85 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole Magnesium | AstraZeneca | Approved | 85 |
| AZD5213 and placebo | AstraZeneca | Phase 2 | 52 |
| fingolimod (FTY720) | Novartis | Phase 1/2 | 41 |
| PF-03654746 + Placebo + Placebo + PF-03654746 | Pfizer | Phase 2 | 51 |
| Aripiprazole | Bristol Myers Squibb | Pre-clinical | 22 |
| NBI-98854 | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 | Neurocrine Biosciences | Phase 1 | 30 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Abobotulinum toxin A | Ipsen | Pre-clinical | 20 |
| GWP42003-P + Placebo | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| trofinetide | Acadia Pharmaceuticals | Phase 3 | 72 |
| Trofinetide | Acadia Pharmaceuticals | Phase 3 | 72 |